60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study
Betsy Goodfellow | July 22, 2024 | News story | Medical Communications | 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials
60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites for the Tafenoquine for Babesiosis study for which it is currently enrolling patients.
The sites included are: Tufts Medical Centre, Yale University and Rhode Island Hospital, all US. The trial is intended to be the world’s first randomised, double-blinded, placebo-controlled clinical trial which will assess the safety and efficacy of tafenoquine for the treatment of human babesiosis patients.
It is planned that between 24-33 hospitalised patients with relapsing babesiosis will be included in the trial, and interim results are expected by September 2025.
Results from a recent study have suggested that tafenoquine combined with standard-of-care has a high cure rate in immunosuppressed patients with relapsing babesiosis for whom prior treatment has failed.
Dr Geoff Dow, chief executive officer of 60 Degrees Pharmaceuticals, commented: “Babesiosis is becoming a top concern within the infectious diseases healthcare community given the fact that accurate diagnosis and treatment are crucial to preventing progression to very serious phases of this illness. Today, a patient who reaches the relapsing stage of babesiosis has few effective treatment options. The Tafenoquine for Babesiosis clinical trial currently enrolling patients is anticipated to shed new light on how best to address the babesiosis treatment needs of this group. The team at 60 Degrees Pharmaceuticals is pleased to partner with Tufts Medical Center, Yale University and Rhode Island Hospital – three of the world’s leading medical centres – in this effort.”
Betsy Goodfellow
Related Content
Evestia Clinical and Atlantic Research Group merge to create global specialist CRO
UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent …
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
